Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Increasing your income can significantly aid in debt repayment. Discover various ways to boost your earnings and pay off debt.
27,939 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Berkshire Hathaway ramps up buybacks and sits on a large cash cushion, while Pershing Square slips 16% year-to-date a...
Gold ETFs still track spot prices, but GLD's 0.40% expense ratio is quietly eroding long-term gains. Through mid-2026...
Insiders are quietly loading up on fintech stocks even as markets wobble. This article explains what those moves coul...
When a juggernaut like Fortnite cools its engagement, the ripple effect hits the entire company. This piece digs into...
Bitcoin and XRP lead the 2026 debate on how to deploy $1,000 in crypto, with macro momentum and policy shifts potenti...
A harsh winter trimmed fishing days and boosted costs for Maine’s lobster sector, even as 2025 revenue stayed above $...
Meta Platforms is pursuing a bold path toward a $9 trillion market cap by 2031. This article breaks down the feasibil...
When a fund trims its Planet Fitness position, it sends a message about risk, growth, and the path for 2026. This dee...
A once-high-flying growth stock tumbled 84% from its peak. This guide explains how to separate a genuine opportunity ...
U.S. stocks fell sharply as fears of broader conflict intensified. The S&P 500 dropped about 1% in early trading, wit...
Embecta faced a sharp decline after its quarterly report, leaving investors wondering about the near-term outlook. Th...